Asthma and COPD Are Not Risk Factors for ICU Stay and Death in Case of SARS-CoV2 Infection.


Journal

The journal of allergy and clinical immunology. In practice
ISSN: 2213-2201
Titre abrégé: J Allergy Clin Immunol Pract
Pays: United States
ID NLM: 101597220

Informations de publication

Date de publication:
01 2021
Historique:
received: 08 07 2020
revised: 06 09 2020
accepted: 18 09 2020
pubmed: 11 10 2020
medline: 2 2 2021
entrez: 10 10 2020
Statut: ppublish

Résumé

Asthmatics and patients with chronic obstructive pulmonary disease (COPD) have more severe outcomes with viral infections than people without obstructive disease. To evaluate if obstructive diseases are risk factors for intensive care unit (ICU) stay and death due to coronavirus disease 2019 (COVID19). We collected data from the electronic medical record from 596 adult patients hospitalized in University Hospital of Liege between March 18 and April 17, 2020, for severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection. We classified patients into 3 groups according to the underlying respiratory disease, present before the COVID19 pandemic. Among patients requiring hospitalization for COVID19, asthma and COPD accounted for 9.6% and 7.7%, respectively. The proportions of asthmatics, patients with COPD, and patients without obstructive airway disease hospitalized in the ICU were 17.5%, 19.6%, and 14%, respectively. One-third of patients with COPD died during hospitalization, whereas only 7.0% of asthmatics and 13.6% of patients without airway obstruction died due to SARS-CoV2. The multivariate analysis showed that asthma, COPD, inhaled corticosteroid treatment, and oral corticosteroid treatment were not independent risk factors for ICU admission or death. Male gender (odds ratio [OR]: 1.9; 95% confidence interval [CI]: 1.1-3.2) and obesity (OR: 8.5; 95% CI: 5.1-14.1) were predictors of ICU admission, whereas male gender (OR 1.9; 95% CI: 1.1-3.2), older age (OR: 1.9; 95% CI: 1.6-2.3), cardiopathy (OR: 1.8; 95% CI: 1.1-3.1), and immunosuppressive diseases (OR: 3.6; 95% CI: 1.5-8.4) were independent predictors of death. Asthma and COPD are not risk factors for ICU admission and death related to SARS-CoV2 infection.

Sections du résumé

BACKGROUND
Asthmatics and patients with chronic obstructive pulmonary disease (COPD) have more severe outcomes with viral infections than people without obstructive disease.
OBJECTIVE
To evaluate if obstructive diseases are risk factors for intensive care unit (ICU) stay and death due to coronavirus disease 2019 (COVID19).
METHODS
We collected data from the electronic medical record from 596 adult patients hospitalized in University Hospital of Liege between March 18 and April 17, 2020, for severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection. We classified patients into 3 groups according to the underlying respiratory disease, present before the COVID19 pandemic.
RESULTS
Among patients requiring hospitalization for COVID19, asthma and COPD accounted for 9.6% and 7.7%, respectively. The proportions of asthmatics, patients with COPD, and patients without obstructive airway disease hospitalized in the ICU were 17.5%, 19.6%, and 14%, respectively. One-third of patients with COPD died during hospitalization, whereas only 7.0% of asthmatics and 13.6% of patients without airway obstruction died due to SARS-CoV2. The multivariate analysis showed that asthma, COPD, inhaled corticosteroid treatment, and oral corticosteroid treatment were not independent risk factors for ICU admission or death. Male gender (odds ratio [OR]: 1.9; 95% confidence interval [CI]: 1.1-3.2) and obesity (OR: 8.5; 95% CI: 5.1-14.1) were predictors of ICU admission, whereas male gender (OR 1.9; 95% CI: 1.1-3.2), older age (OR: 1.9; 95% CI: 1.6-2.3), cardiopathy (OR: 1.8; 95% CI: 1.1-3.1), and immunosuppressive diseases (OR: 3.6; 95% CI: 1.5-8.4) were independent predictors of death.
CONCLUSION
Asthma and COPD are not risk factors for ICU admission and death related to SARS-CoV2 infection.

Identifiants

pubmed: 33038592
pii: S2213-2198(20)31093-X
doi: 10.1016/j.jaip.2020.09.044
pmc: PMC7539890
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

160-169

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Doriane Calmes (D)

Department of Respiratory Medicine, CHU Sart-Tilman B35, Liege, Belgium.

Sophie Graff (S)

Department of Respiratory Medicine, CHU Sart-Tilman B35, Liege, Belgium.

Nathalie Maes (N)

Department of Medico-economics Informations, CHU Sart-Tilman B35, Liege, Belgium.

Anne-Noëlle Frix (AN)

Department of Respiratory Medicine, CHU Sart-Tilman B35, Liege, Belgium.

Marie Thys (M)

Department of Medico-economics Informations, CHU Sart-Tilman B35, Liege, Belgium.

Olivier Bonhomme (O)

Department of Respiratory Medicine, CHU Sart-Tilman B35, Liege, Belgium.

Julien Berg (J)

Department of Respiratory Medicine, CHU Sart-Tilman B35, Liege, Belgium.

Mathieu Debruche (M)

Department of Respiratory Medicine, CHU Sart-Tilman B35, Liege, Belgium.

Fanny Gester (F)

Department of Respiratory Medicine, CHU Sart-Tilman B35, Liege, Belgium.

Monique Henket (M)

Department of Respiratory Medicine, CHU Sart-Tilman B35, Liege, Belgium.

Virginie Paulus (V)

Department of Respiratory Medicine, CHU Sart-Tilman B35, Liege, Belgium.

Bernard Duysinx (B)

Department of Respiratory Medicine, CHU Sart-Tilman B35, Liege, Belgium.

Vincent Heinen (V)

Department of Respiratory Medicine, CHU Sart-Tilman B35, Liege, Belgium.

Delphine Nguyen Dang (DN)

Department of Respiratory Medicine, CHU Sart-Tilman B35, Liege, Belgium.

Astrid Paulus (A)

Department of Respiratory Medicine, CHU Sart-Tilman B35, Liege, Belgium.

Valérie Quaedvlieg (V)

Department of Respiratory Medicine, CHU Sart-Tilman B35, Liege, Belgium.

Frederique Vaillant (F)

Department of Respiratory Medicine, CHU Sart-Tilman B35, Liege, Belgium.

Hélène Van Cauwenberge (H)

Department of Respiratory Medicine, CHU Sart-Tilman B35, Liege, Belgium.

Michel Malaise (M)

Department of Internal Medicine, CHU Sart Tilman B35, Liege, Belgium.

Alisson Gilbert (A)

Emergency Department, CHU Sart-Tilman B35, Liege, Belgium.

Alexandre Ghuysen (A)

Emergency Department, CHU Sart-Tilman B35, Liege, Belgium.

Pierre Gillet (P)

CHU Sart-Tilman B35, Liege, Belgium.

Michel Moutschen (M)

Department of Infectious Diseases, CHU Sart-Tilman B35, Liege, Belgium.

Benoit Misset (B)

Intensive Care Unit, CHU Sart-Tilman B35, Liege, Belgium.

Anne Sibille (A)

Department of Respiratory Medicine, CHU Sart-Tilman B35, Liege, Belgium.

Julien Guiot (J)

Department of Respiratory Medicine, CHU Sart-Tilman B35, Liege, Belgium.

Jean-Louis Corhay (JL)

Department of Respiratory Medicine, CHU Sart-Tilman B35, Liege, Belgium.

Renaud Louis (R)

Department of Respiratory Medicine, CHU Sart-Tilman B35, Liege, Belgium.

Florence Schleich (F)

Department of Respiratory Medicine, CHU Sart-Tilman B35, Liege, Belgium. Electronic address: fschleich@chuliege.be.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH